Abstract #3395

Dopaminergic therapy modulates cortical perfusion in Parkinson’s disease with and without dementia according to ASL perfusion MRI

Chien-Yuan Eddy Lin¹, Wei-Che Lin², Pei-Chin Chen², Yung-Cheng Huang³, Nai-Wen Tsai⁴, Hsiu-Ling Chen², Hung-Chen Wang⁵, Tsu-Kung Lin⁴, Kun-Hsien Chou⁶, Meng-Hsiang Chen², Yi-Wen Chen², and Cheng-Hsien Lu⁴

¹GE Healthcare, Taipei, Taiwan, ²Department of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, ³Department of Nuclear Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, ⁴Department of Neurology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, ⁵Department of Nuerosurgery, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, ⁶Brain Research Center, National Yang-Ming University, Taipei, Taiwan

We examined the cerebral perfusion differences among 17 Parkinson’s disease (PD) patients, 17 PD with dementia (PDD) patients, and 17 healthy controls and used noncontrast arterial spin labelling MRI to assess the effects of dopaminergic therapies on perfusion in the patients. We demonstrated progressive widespread cortical hypoperfusion in PD and PDD and robust effects for the dopaminergic therapies. These patterns of hypoperfusion could be related to cognitive dysfunctions and disease severity. Furthermore, desensitization to dopaminergic therapies in terms of cortical perfusion was found as the disease progressed, supporting the concept that long-term therapies are associated with the therapeutic window narrowing.

This abstract and the presentation materials are available to members only; a login is required.

Join Here